[go: up one dir, main page]

MX2017005235A - Composición farmacéutica de estabilidad mejorada. - Google Patents

Composición farmacéutica de estabilidad mejorada.

Info

Publication number
MX2017005235A
MX2017005235A MX2017005235A MX2017005235A MX2017005235A MX 2017005235 A MX2017005235 A MX 2017005235A MX 2017005235 A MX2017005235 A MX 2017005235A MX 2017005235 A MX2017005235 A MX 2017005235A MX 2017005235 A MX2017005235 A MX 2017005235A
Authority
MX
Mexico
Prior art keywords
lactate
conjugate
pharmaceutical composition
based polymer
improved stability
Prior art date
Application number
MX2017005235A
Other languages
English (en)
Other versions
MX392770B (es
Inventor
Li Yuhua
J Guarino Andrew
Original Assignee
Foresee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Foresee Pharmaceuticals Co Ltd filed Critical Foresee Pharmaceuticals Co Ltd
Publication of MX2017005235A publication Critical patent/MX2017005235A/es
Publication of MX392770B publication Critical patent/MX392770B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P13/00—Preparation of nitrogen-containing organic compounds
    • C12P13/04—Alpha- or beta- amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una composición inyectable para la administración de fármacos por liberación controlada y el proceso de fabricación del mismo, donde la composición comprende: un polímero a base de lactato que tiene un peso molecular promedio en peso de entre 5.000 y 50.000 dalton, un número ácido menor de 3 mg de KOH/g y un contenido de monómeros de lactida residual en el polímero a base de lactato menor de aproximadamente 0,3% en peso; un solvente orgánico farmacéuticamente aceptable: y una sustancia bioactiva o una sal de la misma que contiene un aminoácido sedna en su estructura molecular, que es capaz de reaccionar con el monómero lactida para formar un conjugado; y donde la composición reduce la formación del conjugado.
MX2017005235A 2014-10-15 2015-10-15 Composición farmacéutica de estabilidad mejorada. MX392770B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462064008P 2014-10-15 2014-10-15
PCT/US2015/055634 WO2016061296A1 (en) 2014-10-15 2015-10-15 Pharmaceutical composition with improved stability

Publications (2)

Publication Number Publication Date
MX2017005235A true MX2017005235A (es) 2019-12-11
MX392770B MX392770B (es) 2025-03-19

Family

ID=55747307

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017005235A MX392770B (es) 2014-10-15 2015-10-15 Composición farmacéutica de estabilidad mejorada.
MX2022003939A MX2022003939A (es) 2014-10-15 2017-04-21 Composicion farmaceutica de estabilidad mejorada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003939A MX2022003939A (es) 2014-10-15 2017-04-21 Composicion farmaceutica de estabilidad mejorada.

Country Status (20)

Country Link
US (3) US20160106804A1 (es)
EP (1) EP3207149B1 (es)
JP (2) JP6717839B2 (es)
KR (2) KR102274420B1 (es)
CN (2) CN107075541B (es)
AU (2) AU2015332456A1 (es)
BR (1) BR112017007669A2 (es)
CA (1) CA2964475C (es)
ES (1) ES2949827T3 (es)
HR (1) HRP20230716T1 (es)
HU (1) HUE062326T2 (es)
IL (1) IL251703B (es)
MX (2) MX392770B (es)
PL (1) PL3207149T3 (es)
RS (1) RS64339B1 (es)
RU (1) RU2728786C2 (es)
SA (1) SA517381298B1 (es)
SG (1) SG11201702535QA (es)
SM (1) SMT202300196T1 (es)
WO (1) WO2016061296A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability
AU2017391591B2 (en) * 2017-01-04 2022-12-22 Pharmathen S.A. Process for preparing biodegradable polymers of high molecular weight
EP4011386A1 (en) * 2017-01-31 2022-06-15 Veru Inc. Compositions and methods for long term release of gonadotropin-releasing hormone (gnrh) antagonists
US20200282008A1 (en) * 2017-01-31 2020-09-10 Veru Inc. COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS
GB2568526A (en) 2017-11-20 2019-05-22 Rebio Tech Oy Composition
KR102522654B1 (ko) 2017-12-18 2023-04-17 포시 파마슈티컬스 컴퍼니 리미티드 선택된 방출 기간을 갖는 약제학적 조성물
CN118159252A (zh) 2021-08-05 2024-06-07 美蒂森股份公司 药物组合物
CN116982619A (zh) * 2023-08-04 2023-11-03 洛阳奇泓生物科技有限公司 丙交酯-Nisin固体分散体及其制备

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443340A (en) 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
DE3708916A1 (de) 1987-03-19 1988-09-29 Boehringer Ingelheim Kg Verfahren zur reinigung resorbierbarer polyester
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5487897A (en) 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
ATE168391T1 (de) 1990-04-13 1998-08-15 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung
USRE37950E1 (en) 1990-04-24 2002-12-31 Atrix Laboratories Biogradable in-situ forming implants and methods of producing the same
AU2605592A (en) 1991-10-15 1993-04-22 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
ES2139646T3 (es) 1991-12-19 2000-02-16 Mitsui Chemicals Inc Acido polihidroxido carboxilico y su procedimiento de obtencion.
EP0560014A1 (en) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5681873A (en) 1993-10-14 1997-10-28 Atrix Laboratories, Inc. Biodegradable polymeric composition
DE69524398T2 (de) 1994-04-08 2002-07-18 Atrix Laboratories, Inc. Flüssige mittel zur wirkstoffabgabe
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
TW577759B (en) * 1997-04-18 2004-03-01 Ipsen Pharma Biotech Sustained release compositions in the form of microcapsules or implants and the process for their preparation
FR2776516B1 (fr) * 1998-03-25 2001-05-25 Pharma Biotech Compositions presentant une liberation prolongee et leur procede de preparation
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6756472B1 (en) 1998-12-15 2004-06-29 Takeda Chemical Industries, Ltd. Process for producing polymer
KR100321854B1 (ko) * 1998-12-30 2002-08-28 동국제약 주식회사 루테이나이징 호르몬 릴리싱 호르몬 동족체를 함유하는 장기 서방출성 미립구 및 그의 제조방법
US6355657B1 (en) 1998-12-30 2002-03-12 Atrix Laboratories, Inc. System for percutaneous delivery of opioid analgesics
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
DK1660039T3 (en) * 2003-07-18 2017-01-16 Oakwood Laboratories L L C PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
ES2528720T3 (es) 2004-11-10 2015-02-12 Tolmar Therapeutics, Inc. Sistema de suministro de polímero estabilizado
ES2397712T3 (es) * 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
WO2008008363A1 (en) * 2006-07-11 2008-01-17 Qps, Llc Pharmaceutical compositions for sustained release delivery of peptides
EP3202814B1 (en) * 2007-02-15 2019-10-16 Tolmar Therapeutics, Inc. Low burst poly-(lactide/glycolide) and methods to produce polymers
CA2705520C (en) * 2007-11-13 2016-06-28 Surmodics Pharmaceuticals, Inc. Viscous terpolymers as drug delivery platform
BRPI0918820A2 (pt) 2008-08-29 2016-06-14 Genzyme Corp formulações de peptídeo de liberação controlada e métodos, para aumento de eficiência de carga e para modulação das taxas de liberação por erosão e de difusão inicial, de um agente bioativo em um sistema de liberação baseado em polímero
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability

Also Published As

Publication number Publication date
EP3207149A4 (en) 2018-06-13
RU2017111079A3 (es) 2019-05-17
RU2017111079A (ru) 2018-11-15
ES2949827T3 (es) 2023-10-03
AU2019279929B2 (en) 2021-02-25
SG11201702535QA (en) 2017-04-27
HUE062326T2 (hu) 2023-10-28
JP2017531697A (ja) 2017-10-26
CN107075541B (zh) 2021-06-25
JP2020147595A (ja) 2020-09-17
CA2964475A1 (en) 2016-04-21
SMT202300196T1 (it) 2023-09-06
US20160106804A1 (en) 2016-04-21
KR102134873B1 (ko) 2020-07-17
MX2022003939A (es) 2022-04-25
KR20170070176A (ko) 2017-06-21
EP3207149C0 (en) 2023-06-07
PL3207149T3 (pl) 2023-08-21
JP6717839B2 (ja) 2020-07-08
IL251703A0 (en) 2017-06-29
CA2964475C (en) 2020-03-24
CN107075541A (zh) 2017-08-18
US20250041378A1 (en) 2025-02-06
MX392770B (es) 2025-03-19
NZ730538A (en) 2024-01-26
BR112017007669A2 (pt) 2017-12-19
CN113209009A (zh) 2021-08-06
IL251703B (en) 2021-03-25
CN113209009B (zh) 2024-08-20
RS64339B1 (sr) 2023-08-31
HRP20230716T1 (hr) 2023-10-13
AU2019279929A1 (en) 2020-01-16
KR102274420B1 (ko) 2021-07-08
AU2015332456A1 (en) 2017-04-13
EP3207149A1 (en) 2017-08-23
WO2016061296A1 (en) 2016-04-21
JP6928695B2 (ja) 2021-09-01
KR20190029783A (ko) 2019-03-20
US20220160817A1 (en) 2022-05-26
EP3207149B1 (en) 2023-06-07
SA517381298B1 (ar) 2021-12-18
RU2728786C2 (ru) 2020-07-31

Similar Documents

Publication Publication Date Title
MX2022003939A (es) Composicion farmaceutica de estabilidad mejorada.
ES2552651T3 (es) Composición inyectable de polidesoxirribonucleótido para el tratamiento de enfermedades osteoarticulares
CL2014003215A1 (es) Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 31 y 43 kda y una viscosidad inherente entre 0,27 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion
CL2014003216A1 (es) Composicion de liberacion sostenida inyectable por via intramuscular, que comprende un farmaco, un copolimero biocompatible a base de acido lactico y acido glicolico, con un peso molecular entre 30 y 46 kda y una viscosidad inherente entre 0,25 y 0,31 dl/g, y dmso como disolvente; kit farmaceutico; y metodo para su elaboracion.
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
AR090491A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo
CO6670598A2 (es) Forma de dosificación resistente a alteración que comprende un polímero aniónico
PE20080765A1 (es) Formas de dosificacion farmaceutica
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
PE20171622A1 (es) Formulacion de relacion fija de insulina glargina/lixisenatida
MX2019010189A (es) Polisulfato de pentosan, composicion farmaceutica y anticoagulante.
UA114088C2 (xx) Лікарська композиція з пролонгованим вивільненням для ін'єкцій
RU2018118986A (ru) Фармацевтическая композиция для введения в слизистую носа
PE20130782A1 (es) Composiciones farmaceuticas que consisten de paracetamol y el proceso para la preparacion del mismo
AR099921A1 (es) Composición polimérica de acrilato reticulable
MX374938B (es) Un método para el tratamiento de trastornos del movimiento con befiradol.
WO2016027160A3 (en) Nasal composition comprising mixture of hyaluronic acids and saline solution
MX2012003860A (es) Formulacion de liberacion controlada de carvedilol.
MX2016004660A (es) Composiciones de peptido novedosas.
MX2017004378A (es) Formulaciones farmaceuticas de liposomas pegilados y factores de coagulacion sanguinea.
HK1255848A1 (zh) 用於关节内浸润疗法的可注射液体组合物
AR074470A1 (es) Compuesto de amida del acido ciclopropanocarboxilico, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de diabetes
AR110595A1 (es) Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos